1. Search Result
Search Result
Results for "

Lixisenatide

" in MedChemExpress (MCE) Product Catalog:

3

Inhibitors & Agonists

3

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0119
    Lixisenatide
    1 Publications Verification

    GCGR MEK Akt MMP JNK Neurological Disease Metabolic Disease Inflammation/Immunology
    Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe −/− Irs 2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .
    <em>Lixisenatide</em>
  • HY-P0119A
    Lixisenatide acetate
    1 Publications Verification

    GCGR Metabolic Disease
    Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).
    <em>Lixisenatide</em> acetate
  • HY-P0119R

    GCGR MEK Akt MMP JNK Neurological Disease Metabolic Disease Inflammation/Immunology
    Lixisenatide (Standard) is the analytical standard of Lixisenatide. This product is intended for research and analytical applications. Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe −/− Irs 2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .
    <em>Lixisenatide</em> (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: